Menu

Redirecting Gene Therapy Restores Sight

By targeting rhodopsin genes to neurons, scientists help blind mice see.

Aug 17, 2015
Amanda B. Keener

WIKIMEDIA, SANTIAGO RAMON Y CAJAL

A team of researchers at the University of Manchester enabled blind mice with advanced retinal degeneration to see by delivering the gene for a light-sensing protein into nervous cells within their retinas, according to a study published last month (July 30) in Current Biology.

“This is the most effective example yet of the use of genetic therapy to treat advanced retinal degeneration,” Robin Ali, who studies gene therapy at University College London and was not involved in the work told New Scientist.

Researchers have previously used virus-based gene therapies to replace lost or defective genes in rods and cones, the photoreceptor cells of the retina. But for the present study, the team set its sights on ganglion and bipolar cells, which transduce signals from rods and cones into electrical signals sent to the brain. By delivering the gene for the light-sensing pigment, rhodopsin to these cells they bypassed the need for rods and cones. Doing so enabled the treated mice to respond to visual stimuli, such as a video of an owl swooping.

“The treated mice could discriminate black and white bars, but only ones that were 10 times thicker than what sighted mice could see,” Robert Lucas, study coauthor and geneticist at the University of Manchester told New Scientist.

Lucas added that the virus they used to deliver the gene is approved for use in humans, which means trials in humans could begin in the next five years.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!